Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7891 to 7905 of 8922 results

  1. Gantenerumab for treating early Alzheimer's disease [ID6142]

    In development Reference number: GID-TA11269 Expected publication date: TBC

  2. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [ID6247]

    In development Reference number: GID-TA11251 Expected publication date: TBC

  3. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A [ID6312]

    In development Reference number: GID-TA11329 Expected publication date: TBC

  4. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

  5. Developing NICE guidelines: how to get involved (PMG22)

    October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.

  6. Process manual for the endorsement of guidance and quality standard support resources (PMG29)

    The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.

  7. Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.

  8. Process guide for adoption support resources for health technologies (PMG23)

    This process and methods guide has been withdrawn.

  9. Medical technologies evaluation programme methods guide (PMG33)

    This medical technologies evaluation programme methods guide has been replaced by the NICE HealthTech programme manual.

  10. Into practice guide (PMG30)

    This guide has been updated and replaced by practical steps to improving the quality of care and services using NICE guidance.

  11. Health technology evaluations: interim methods and process guide for the proportionate approach to technology appraisals (PMG40)

    This interim methods and process guide for the proportionate approach to technology appraisals has been incorporated into NICE health technology evaluations: the manual.

  12. Medical technologies evaluation programme process guide (PMG34)

    This medical technologies evaluation programme process guide has been replaced by the NICE HealthTech programme manual.

  13. Key therapeutic topics – Medicines management options for local implementation: Interim process statement (PMG7)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics. We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy. If you have any queries, please contact nice@nice.org.uk.

  14. Canagliflozin for treating type 2 diabetes in people 10 to 17 years [ID6352]

    In development Reference number: GID-TA11377 Expected publication date: TBC

  15. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024